The Commission on Classification and Terminology and the Commission on Epidemiology of the International League Against Epilepsy (ILAE) have charged a Task Force to revise concepts, definition, and classification of status epilepticus (SE). The proposed new definition of SE is as follows: Status epilepticus is a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures (after time point t 1 ). It is a condition, which can have long-term consequences (after time point t 2 ), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures. This definition is conceptual, with two operational dimensions: the first is the length of the seizure and the time point (t 1 ) beyond which the seizure should be regarded as "continuous seizure activity." The second time point (t 2 ) is the time of ongoing seizure activity after which there is a risk of long-term consequences. In the case of convulsive (tonic-clonic) SE, both time points (t 1 at 5 min and t 2 at 30 min) are based on animal experiments and clinical research. This evidence is incomplete, and there is furthermore considerable variation, so these time points should be considered as the best estimates currently available. Data are not yet available for other forms of SE, but as knowledge and understanding increase, time points can be defined for specific forms of SE based on scientific evidence and incorporated into the definition, without changing the underlying concepts. A new diagnostic classification system of SE is proposed, which will provide a framework for clinical diagnosis, investigation, and therapeutic approaches for each patient. There are four axes: (1) semiology; (2) etiology; (3) electroencephalography (EEG) correlates; and (4) age. Axis 1 (semiology) lists different forms of SE divided into those with prominent motor systems, those without prominent motor systems, and currently indeterminate conditions (such as acute confusional states with epileptiform EEG patterns). Axis 2 (etiology) is divided into subcategories of known and unknown causes. Axis 3 (EEG correlates) adopts the latest recommendations by consensus panels to use the following descriptors for the EEG: name of pattern, morphology, location, time-related features, modulation, and effect of intervention. Finally, axis 4 divides age groups into neonatal, infancy, childhood, adolescent and adulthood, and elderly.
Introduction
Status epilepticus (SE), considered the most extreme form of a seizure, was included in the classification of seizures of the International League Against Epilepsy (ILAE) of 1970 1 and 1981. 2 In the first ILAE Classification of Seizures, which was developed in 1964 and approved in 1970, 1 SE was defined in the addendum of the publication as a "seizure that persists for a sufficient length of time or is repeated frequently enough to produce a fixed and enduring condition." SE was divided into partial, generalized, or unilateral types, and basically mirrored the seizure classification. 1, 3 In the revision of 1981, the definition was minimally changed into a "seizure" that "persists for a sufficient length of time or is repeated frequently enough that recovery between attacks does not occur." 2 Again, the distinction between partial, generalized, and epilepsia partialis continua (EPC) was mentioned in the addendum of the Classification, without further details. 2 These concepts, although highly valuable, were imprecise, as they did not define the duration of a seizure that was "fixed and enduring" or "sufficient length," nor was there a clinical description (semiology) of the type of SE in the Classification of 1970 and its 1981 revision. These issues were not resolved with the report of the Core Group on Classification. 4 The ILAE recognized the need to revise the Classification of SE 
Purpose of Classification
Classification refers to the way in which items are organized and should be ideally based on the underlying neurobiology to form natural classes or entities. 5 Because current knowledge regarding the pathophysiology and the underlying neurobiology of status epilepticus is far from complete, a proposed classification can be only a compromise between a conceptual, scientific (drawing on what is known) and pragmatic empirical classification. 6 A classification has to serve several purposes. First, it has to facilitate communication between clinicians by providing them with a common language. The classes should be clinically differentiated. Second, classification should help to improve the treatment of patients, based on current understanding of pathophysiology, prognosis, etiology, and age. Third, classification should permit the conduct of epidemiologic studies of consequences and prevention. Fourth, classification should guide basic research to identify natural classes (i.e., entities or diseases sensu strictu), which in turn will form the basis of a true scientific classification in the future. Therefore, it is important to emphasize that the proposed classification is merely a framework and must not be treated as a doctrine, but reflect our current knowledge on status epilepticus. Future advances in basic, epidemiologic, and clinical research will undoubtedly lead to modifications and major revisions of this proposed classification of SE.
A classification of SE cannot simply reflect the classification of seizure types, since symptoms and signs during the fixed stage of SE frequently are different compared to symptoms during short-lasting seizures. At least half of the patients presenting with SE do not have epilepsy, and acute neurologic disorders and the long duration of status leads to significant variability in its clinical presentation (i.e., semiology). SE is not a disease entity but rather a symptom with a myriad of etiologies.
Definition of Status Epilepticus
A seizure is defined as "a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. The term transient is used as demarcated in time, with a clear start and finish." Classically SE was defined as a "a condition characterized by an epileptic seizure that is sufficiently prolonged or repeated at sufficiently brief intervals so as to produce an unvarying and enduring epileptic condition." 7, 8 Because the ILAE definitions of SE have not provided a precise definition of the duration of SE, 1-5 different opera-tional definitions have been provided in textbooks, research papers, and clinical trials. The seminal work by Meldrum et al. 9 suggested that 82 min or longer of ongoing seizure activity in baboons can cause irreversible neuronal injury due to excitotoxicity. This observation led to the commonly used definition for SE as seizure duration of 30 min. 10, 11 The rationale behind this definition was that irreversible neuronal injury may occur after 30 min of ongoing seizure activity. This definition, therefore, remains useful for epidemiologic studies focused on consequences and prevention of SE. Clinicians have rightfully argued for the need to start treatment earlier, because the prognosis of SE worsens with increasing duration. 12, 13 Several suggestions of a shorter timeframe for SE have subsequently been made, but none has been based on scientific evidence provided by prospective studies.
This problem was addressed in an article by Lowenstein et al. 14 The obvious discrepancy between the limited knowledge of the pathophysiology and the need to treat patients rapidly led to the concept of an operational and a conceptual definition. Generalized convulsive SE in adults and children older than 5 years was operationally defined as ". . .≥5 min of (1) continuous seizure or (2) two or more discrete seizures between which there is incomplete recovery of consciousness," 14 This time frame has been generally accepted by the clinical community and used to guide when emergency treatment of generalized convulsive SE should commence. As a basic research (or conceptual) definition, the ILAE Core Group on Classification group suggested the following: "Generalized, convulsive status epilepticus refers to a condition in which there is failure of the "normal" factors that serve to terminate a typical GTCS [generalized tonic-clonic seizures]." 15 Although this distinction between a pragmatic, operational definition and a basic research definition of generalized convulsive status has guided the treatment of generalized convulsive SE, other forms of SE have not been addressed.
The ILAE Task Force on Classification of Status Epilepticus proposes a definition that encompasses all types of SE, and takes into consideration current knowledge regarding the pathophysiology of SE and the need to address clinical treatment decision making time points, as well as the conduct of epidemiologic and clinical studies:
SE is a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms which lead to abnormally prolonged seizures (after time point t 1 ). It is a condition that can have long-term consequences (after time point t 2 ), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures.
This definition is conceptual, with two operational dimensions: the first is the length of the seizure and the time point (t 1 ) at which the seizure should be regarded as an "abnormally prolonged seizure." The second time point (t 2 ) is the time of ongoing seizure activity beyond which there is a risk of long-term consequences. In the case of convulsive (tonic-clonic) SE, both time points are based on animal experiments and clinical research. This evidence is incomplete; there is furthermore considerable variation, so these time points should be considered as the best estimates currently available. Data are not yet available for other forms of SE, but as knowledge and understanding increases, time points can be defined for specific forms of SE based on scientific evidence and incorporated into the definition, without changing the underlying concepts. This division into two time points has clear clinical implications: The time point of operational dimension 1 determines the time at which treatment should be considered or started, whereas the time point of operational dimension 2 determines how aggressively treatment should be implemented to prevent long-term consequences. The time domain may vary considerably between different forms of SE.
Data from select populations with refractory epilepsy undergoing video-electroencephalography (EEG) monitoring indicate that most convulsive seizures last <5 min. [16] [17] [18] [19] [20] In unselected community-based populations, the data suggest that the estimated duration of seizures >5 min is much more common than suggested by inpatient monitoring and that ≥10% of first unprovoked seizures last longer than 30 min. 20, 21 Observations from a less selected pediatric population show that there are two subgroups of patients, one with a tendency to brief seizures (<5 min) and the other subgroup that represents a significant minority of patients with a propensity to more prolonged seizures. 20 In this study, a seizure that lasted >7 min was likely to be prolonged and therefore required acute treatment. Taken together, these findings led the Task Force to reach a consensus opinion that treatment of convulsive seizures should be initiated at around 5 min.
Given the experimental evidence indicating irreversible brain damage after prolonged seizures 9 and the potential threat of brain damage in humans, we suggest the time of t 2 at 30 min in convulsive SE, in line with previous definitions of SE. 10, 11 As in the animal experimentation, considerable variation in the duration of prolonged seizures that result in damage has been found, but this time point is chosen on the basis of providing a practical safe guideline for clinical purposes. There is limited information to define t 1 and t 2 in focal SE, 19, 22 and no information for absence SE (see Table 1 ). Furthermore, the likelihood of damage is dependent on the location of the epileptic focus (also true in experimental animals), the intensity of the status, the age of the patient, and other factors, and research is needed to define these aspects further. It must be emphasized that the time limits given in Table 1 are meant primarily for operational purposes. They are general approximations only, and the timing of onset of cerebral damage will vary considerably in different clinical circumstances.
Comment: Axes
The purpose of the diagnostic axes is to provide a framework for clinical diagnosis, investigation, and therapeutic approaches for each patient. 1, 4 Previously, in 1970, the axes encompassed (1) clinical seizure type, (2) electroencephalographic ictal and interictal expression, (3) anatomic substrate, (4) etiology, and (5) age. In the 1981 revision, the axes were limited to the seizure type and EEG expression (ictal and interictal) (Classification 1981). At least half of the patients with SE do not have epilepsy or specific epilepsy syndromes-they have SE due to acute or remote central nervous system or systemic illness. Therefore, the axes used previously in seizure classification need to be modified for the classification of status epilepticus.
Classification of Status Epilepticus
For classification of SE we propose the following four axes:
1 Semiology 2 Etiology 3 EEG correlates 4 Age Ideally, every patient should be categorized according to each of the four axes. However, it is acknowledged that this will not always be possible. At initial presentation, the approximate age of the patient and the semiology will be immediately assessable. The etiology will be apparent less frequently and may take time to identify. It is also recognized that EEG recordings will not be available in many settings, particularly at presentation. However, the EEG will affect choice and aggressiveness of treatment, prognosis, and clinical approaches, so an EEG should be sought where possible and as early as possible. In fact, some forms of SE may only be reliably diagnosed by EEG. 23 Like in other acute neurologic conditions, the semiology (symptoms and signs) and the EEG pattern in SE are highly dynamic and may change over short time periods in a given patient. Thus, repeated neurologic examinations and EEG investigations in a patient with SE may lead to a different classification. For example, SE may start with focal motor symptoms evolving into bilateral convulsive SE (A.1.b) and may present a few hours later as nonconvulsive SE (NCSE) with coma and minor motor phenomena resembling so called "subtle status" (B.1). Likewise, the EEG may show lateralized periodic discharges at the beginning and a bilateral synchronous pattern at the second investigation.
Axis 1: Semiology
This axis refers to the clinical presentation of SE and is therefore the backbone of this classification. The two main taxonomic criteria are: 1. The presence or absence of prominent motor symptoms 2 The degree (qualitative or quantitative) of impaired consciousness Those forms with prominent motor symptoms and impairment of consciousness may be summarized as convulsive SE as opposed to the nonconvulsive forms of SE (NCSE). Although the term convulsion is sometimes disregarded as a lay term, it reflects the clinician 0 s ordinary language. In fact "status epilepticus" is also a lay term, as it is the English translation of etat de mal, which was used in the 19th century by patients in the Salpêtri ere. 24 Thus, it was decided to keep the well-accepted term "convulsive." It designates "episodes of excessive abnormal muscle contractions, usually bilateral, which may be sustained, or interrupted" 25 ( Table 2) . 
Axis 2: Etiology
The underlying cause (etiology) of SE is categorized in a manner that is consistent with the concepts of the ILAE Commission for Classification proposal 2010, 5 but acknowledges the well-established terms that are used by epileptologists, emergency doctors, neurologists, pediatric neurologists, neurosurgeons, family doctors, and other clinicians looking after patients with SE (Table 3) .
The term "known" or "symptomatic" is used-consistent with the common neurologic terminology-for SE caused by a known disorder, which can be structural, metabolic, inflammatory, infectious, toxic, or genetic. Based on its temporal relationship, the subdivisions acute, remote, and progressive can be applied.
The term "idiopathic" or "genetic" is not applicable to the underlying etiology of SE. In idiopathic or genetic epilepsy syndromes, the cause of status is not the same as for the disease, but some metabolic, toxic, or intrinsic factors (like sleep deprivation) may trigger SE in these syndromes. Therefore, the term "idiopathic" 28 or "genetic" 5 is not used here. SE in a patient with juvenile myoclonic epilepsy (which itself is "idiopathic" or "genetic") can be symptomatic, due to inappropriate antiepileptic drug (AED) treatment, abrupt drug withdrawal, or drug intoxication.
The term "unknown" or "cryptogenic" (Greek: jqύpsοϛ, hidden or unknown, s o cέmοϛ, family, class, descent, origin) is used in its strict original meaning: unknown cause. The assumption that it is "presumably" symptomatic or genetic is inappropriate. Synonymously and consistent with the proposal 2010, 5 the term "unknown" or appropriate translations in different languages can be used (Table 4) . SE in its varied forms has a plethora of causes; a list is attached (Appendix 1). The list will be updated periodically and will provide a database for clinicians.
Axis 3: Electroencephalographic correlates
None of the ictal EEG patterns of any type of SE is specific. Epileptiform discharges are regarded as the hallmark, but with increasing duration of SE, the EEG changes and rhythmic nonepileptiform patterns may prevail. Similar EEG patterns, such as triphasic waves, can be recorded in various pathologic conditions, leading to substantial confusion in the literature. Although the EEG is overloaded with movement and muscle artifact in the convulsive forms of SE and thus of limited clinical value, it is indispensable in the diagnosis of NCSE, as the clinical signs (if any) are often subtle and nonspecific. 23, 29 Advances in electrophysiologic techniques may provide us with increased capability to utilize EEG in the emergency setting and allow better delineation of the highly dynamic changes of EEG patterns in the near future.
Currently there are no evidence-based EEG criteria for SE. Based on large descriptive series and consensus panels, 26, 27, [30] [31] [32] we propose the following terminology to describe EEG patterns in SE: 1 Location: generalized (including bilateral synchronous patterns), lateralized, bilateral independent, multifocal. 2 Name of the pattern: Periodic discharges, rhythmic delta activity or spike-and-wave/sharp-and-wave plus subtypes. 3 Morphology: sharpness, number of phases (e.g., triphasic morphology), absolute and relative amplitude, polarity. Examples of SE that occur in different age groups, are listed in Table 5 and Figure 1 . SE in neonates may be subtle and difficult to recognize. Some forms of SE are seen as an integral part of the electroclinical syndrome; others can occur in patients within a certain electroclinical syndrome, or when trigger factors or precipitating causes are present, such as sleep deprivation, intoxication, or inappropriate medication. Examples are phenytoin in some forms of progressive myoclonic epilepsies, 33 carbamazepine in juvenile myoclonic epilepsy, 34, 35 or absence epilepsies. 36 
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